Table 3 Combination regimen
Regimens | All (n = 49) |
|---|---|
Immunotherapy, n (%) | Â |
 Camrelizumab | 16 (32.7%) |
 Tislelizumab | 10 (20.4%) |
 Pembrolizumab | 8 (16.3%) |
 Sintilimab | 6 (12.2%) |
 Toripalimab | 5 (10.2%) |
 Nivolumab | 4 (8.2%) |
 Durvalumab | 1 (2.0%) |
 Atezolizumab | 1 (2.0%) |
Chemotherapy or targeted therapy, n (%) | Â |
 Carboplatin | 19 (38.8%) |
 Nedaplatin | 10 (20.4%) |
 Cisplatin | 3 (6.1%) |
 Anlotinib | 3 (6.1%) |
 Lobaplatin | 3 (6.1%) |
 Apatinib | 1 (2.0%) |
 Endostar | 1 (2.0%) |